BAFNAPH vs VINEETLAB: Stock Comparison

Bafna Pharmaceuticals Limited vs Vineet Laboratories Limited

Live data: 9 June 2026, 4:08 PM IST • Source: NSE and company filings

Bafna Pharmaceuticals Limited is the larger company by market capitalisation. Bafna Pharmaceuticals Limited shows faster revenue growth, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bafna Pharmaceuticals Limited and Vineet Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BAFNAPH is more favourable on 8 of 10 scored metrics and VINEETLAB on 1These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BAFNAPH is the larger company
₹562 Cr vs ₹73 Cr
EPS
BAFNAPH has higher earnings per share
₹4.09 vs ₹-20.47
Revenue Growth (TTM YoY)
BAFNAPH has faster revenue growth
15.4% vs 11.05%
EPS Growth (TTM YoY)
BAFNAPH has faster EPS growth
95% vs 0%
Qtr Sales Growth
BAFNAPH has stronger quarterly sales growth
30.9% vs -68.8%
Qtr Profit Growth
VINEETLAB has stronger quarterly profit growth
59.2% vs 53.9%
ROCE
BAFNAPH has a higher ROCE
-3% vs -28%
Net Margin
BAFNAPH has a higher net margin
7.37% vs -26.92%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBAFNAPHVINEETLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBAFNAPHVINEETLAB
Live Price₹174.58₹38.55
Day Change-10%5.79%
Volume2.84 L2.02 L
52-Week High₹213.36₹49.99
52-Week Low₹78.18₹27.96
Distance from 52W High-18.18%-22.88%

Valuation

MetricBAFNAPHVINEETLAB
Market Cap₹562 Cr₹73 Cr
P/E Ratio0x
P/B Ratio0x
EPS₹4.09₹-20.47
Book Value₹38.54₹15.84
Dividend Yield0%0%

Growth

MetricBAFNAPHVINEETLAB
Revenue Growth (TTM YoY)15.4%11.05%
EPS Growth (TTM YoY)95%0%
Qtr Sales Growth30.9%-68.8%
Qtr Profit Growth53.9%59.2%

Profitability & Leverage

MetricBAFNAPHVINEETLAB
ROE11.54%
ROCE-3%-28%
Net Margin7.37%-26.92%
Operating Margin9.71%-22.4%
Debt to Equity0.39x2.73x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricBAFNAPHVINEETLAB
Promoter Holding75%5.98% 6.48 pp
FII Holding9.34%0.36% 0.36 pp
DII Holding0%
Public Holding15.66%93.66% 6.12 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bafna Pharmaceuticals Limited and Vineet Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.